Using Nanoparticles to Activate Immune Cells to Fight Tumors

University of Iowa
Iowa City, Iowa
BiologyMedicine
DOI: 10.18258/3518
$1,931
Raised of $1,500 Goal
128%
Funded on 12/19/14
Successfully Funded
  • $1,931
    pledged
  • 128%
    funded
  • Funded
    on 12/19/14

Discussion

Join the conversation!Sign In
  • David Johnston
    David Johnston
    Your method of fighting cancer of costimulation of B-cell receptor (BCR) and Toll-like receptor 7 (TLR7) with nanoparticles prior to injecting B cells is superior to injecting nanoparticles into the patient to stimulate T cells, BCR & TLR7, ie. Patent US20110104293 Example 21. The role of TLR7 in M2 macrophage polarization is intriguing.
    Dec 02, 2015
  • David Johnston
    David Johnston
    Thank you Gail.
    Nov 26, 2015
  • Gail A. Bishop
    Gail A. BishopResearcher
    David, Thank you for your interest. But I want to clear up some areas of confusion. B cells express TRAF3 constitutively; they don't need exogenous stimuli. The nanoparticles are to enhance B cell uptake of antigen and adjuvant signals, which in turn makes them more effective APC. My lab performed a proof-of-concept of the B cell vaccine approach in an infectious disease mouse model; you can find the paper in The Journal of Immunology (2009). This paper would give you a clearer idea of our approach than I could provide in a quick paragraph. Using the approach for tumors is newer for us, and we need to do more work to be certain of the molecular mechanisms. We do know thta CD8 T cell activation is stimulated, but are not sure of the role of macrophages at this point. Best, GB
    Nov 24, 2015
  • David Johnston
    David Johnston
    The nanoparticles must be needed to cause the B cells to express TRAF3. I am confident that this can be done with nanoparticles because Gail Bishop succeeded in doing it five years ago: "Differential TRAF3 utilization by a variant human CD40 receptor with enhanced signaling"
    Nov 22, 2015
  • David Johnston
    David Johnston
    I think I understand your treatment now. Your B cells express TRAF3 which downregulates IL-10 to polarize macrophages to M1 type cells & undermine the tumors survival mechanism. Additional reference: "TNFR-Associated Factor-3 Is Associated With BAFF-R and Negatively Regulates BAFF-R-Mediated NF-B Activation and IL-10 Production"  . In summary, your treatment uses B cells expressing TRAF3 & newly polarized M1 cells to combat tumors. Thats a great idea. 
    Nov 22, 2015
  • David Johnston
    David Johnston
    Since you are dealing with Melanoma, please keep this in mind: "Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation"  .Just in case your treatment of Melanoma falls short, you can might be able to work something out with this inventor: US20150080940 "Anti-tumor macrophage m1 morphology inducer" .You have an brilliant idea. No radiation. No chemotherapy. I am excited about the prospect of fighting cancer naturally with the immune system. I hope the FDA approves you all the way & doesnt limit your treatment availability & capabilities. The Burzynski Clinic was forced by the FDA to avoid tailor made treatments in replacing missing Histone Deacetylase Inhibitors resulting in questionable outcomes. Good luck.
    Nov 19, 2015
  • David Johnston
    David Johnston
    Did I understand it right, when you say Bvac, does that mean that you are using "B cells" as antigen-presenting cells (APCs)? That you are applying Endogenous generated antigens from within the tumor cells (ie retroviruses, etc) & using the nanoparticles as an antigen catalyst to program the APCs that you removed before injecting them. I stand corrected from my previous entry. Keep up the good work.
    Nov 19, 2015
  • David Johnston
    David Johnston
    Thank you, are you referring to: "Doxorubicin-Loaded Nanoparticles for the Induction of Anti-Tumor Immune Responses" Am I correct to say that they both involve the expression of Calreticulin?  ie UVB light induced retroviruses: "Pathophysiological Roles of Calreticulin in Autoimmune Disease" 
    Nov 19, 2015
  • Gail A. Bishop
    Gail A. BishopResearcher
    I'm sorry you got that incorrect impression, David. We are using Bvac as antigen presenting cells, NOT to make antibodies. This is quite a different goal. Regards, GB
    Nov 18, 2015
  • David Johnston
    David Johnston
    You said that you wanted to create antibodies in Melanoma cells. You are reinventing the wheel. This can be done on the cheap, see "Transcriptional Activation of Endogenous Retroviral Sequences in Human Epidermal Keratinocytes by UVB Irradiation"
    Nov 18, 2015
  • David Johnston
    David Johnston
    You said that you wanted to create antibodies in Melanoma cells. You are reinventing the wheel. This can be done on the cheap, see "Transcriptional Activation of Endogenous Retroviral Sequences in Human Epidermal Keratinocytes by UVB Irradiation"
    Nov 18, 2015
  • Annie Edmonds
    Annie Edmonds
    Never give up! What you're doing is going to one day help so many people..Thank you for your dedication..
    Dec 12, 2014
  • Gail A. Bishop
    Gail A. BishopResearcher
    Thank you for the kind words, Annie. Much appreciated. Happy holidays, Gail
    Dec 18, 2014
  • Abby Hanson
    Abby HansonBacker
    Good luck! I wish you much success in such important research!
    Nov 13, 2014
  • Lee
    LeeBacker
    I wish you and your team the very best of luck with this research!
    Nov 12, 2014
  • Jonas V Butkus
    Jonas V ButkusBacker
    Insurance for my later years.
    Nov 04, 2014
  • Brett Hanson
    Brett HansonResearcher
    Jonas, thanks for your donation. It will go to good use!
    Nov 04, 2014
  • Harlan Hanson
    Harlan HansonBacker
    Good Luck-Papa & Grammy
    Nov 02, 2014
  • Jeff Huber
    Jeff HuberBacker
    I'd love to learn more. Are there some papers or journal articles on your approach you can point me to? Thanks!
    Oct 30, 2014
  • Gail A. Bishop
    Gail A. BishopResearcher
    Jeff, Many thanks for your interest and support. Brett will be sending you a published report from our lab and a recent review article that explains more about this approach and our rationale. Regards, Gail Bishop
    Oct 31, 2014
  • Brett Hanson
    Brett HansonResearcher
    Thanks again for your donation. Below are a couple links to relevant papers. If you can't access them, you can email me at brett-m-hanson@uiowa.edu and I'll send you pdf's. http://www.jimmunol.org/content/183/8/4833.long http://www.sciencedirect.com/science/article/pii/S1549963410002364 http://www.sciencedirect.com/science/article/pii/S1471490604002960
    Nov 03, 2014
  • Mark Hanson
    Mark HansonBacker
    Hope your project gets funded and yields some useful results
    Oct 30, 2014
  • Dan Abendroth
    Dan AbendrothBacker
    Rooting for a breakthrough!
    Oct 29, 2014
  • Allen Bishop
    Allen BishopBacker
    Glad to contribute
    Oct 28, 2014
  • Gail A. Bishop
    Gail A. BishopResearcher
    Thank you, Allen! That is really appreciated. Gail
    Oct 28, 2014
  • WJ Park
    WJ ParkBacker
    Good luck!
    Oct 22, 2014
  • Ann Calano
    Ann CalanoBacker
    Good luck!
    Oct 22, 2014